AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...

Power Lifetm by Tony Horton, the premium supplement brand designed to fuel active, healthy living, is celebrating its 5th anniversary. Since its launch in 2020, Power Life has become a game changer in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

2024 Healthcare & Pharmaceuticalscategory Corcept Therapeutics' ALS drug fails in mid-stage trial December 11, 2024 Healthcare & Pharmaceuticalscategory Malaria cases up again in 2023, African ...

The rebel leader who helped oust the Assad regime calls on countries to hand over “criminals” who fled Syria. A new caretaker prime minister warns that the country faces a dire financial ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

US Bankers Are Cautious Towards Cryptos Despite Upcoming Pro-Crypto Administration ...